Publication date: Nov 12, 2024
The unprecedented global spread of monkeypox (mpox) has reinvigorated the pursuit of next-generation poxvirus vaccines. Given the success of the mRNA-lipid nanoparticle (LNP) vaccine platform to vaccinate against SARS-CoV-2, candidate poxvirus mRNA vaccines, as recently reported by Zuiani et al. and Mucker et al. , demonstrate success in nonhuman primate (NHP) models and provide insights into the basis of the protective immune response.
Concepts | Keywords |
---|---|
18th | immune profiling |
Models | lipid nanoparticle |
Monkeypox | mRNA |
Nanoparticle | nonhuman primate |
Vaccines |
Semantics
Type | Source | Name |
---|---|---|
disease | MESH | monkeypox |
drug | DRUGBANK | Spinosad |
disease | IDO | immune response |
Original Article
(Visited 1 times, 1 visits today)